How We’re Buying <br>into Stem Cell Therapy Research

Why shouldn’t Christians promote and participate in studies that may help cure terminal diseases and paralyzing injuries?

Click on the order button below to download this Current Issues Bible Study as a Microsoft Word file.

Overview

The U.S. government continues to debate whether to pursue stem cell therapy research. True, embryos are destroyed in the process of trying to save people with life-threatening illnesses or injuries, but, according to late actor Christopher Reeves, the government must approve such research because its job is to do the greatest good for the greatest number of people. What’s our response?

Table of Contents

SCRIPTURE: Genesis 1:26-28; 4:8-16; 9:1-7. Acts 15:1-35. Matthew 5:45b; 6:33; 7:12; 18:14; 22:37-40

LEADER'S GUIDE

    • Identify the Current Issue

    • Discover the Eternal Principles

Teaching point one: All life is created by God. Humans are created in the image of God, thereby reflecting their Creator.
Teaching point two: God is not just the creator of human life; he also wills to protect the human life he has created.
Teaching point three: God makes provision for human livelihood—both plant and animal life—but taking the life of a human being created in God’s image is prohibited.
Teaching point four: The Bible doesn’t have an answer for every human dilemma, but with the aid of the Spirit in the community of faith, it points us in the right direction.
Teaching point five: Even if the Bible doesn’t have an answer for every human dilemma, it has many principles that apply to matters of life and death.
    • Apply Your Findings

ARTICLE FROM CHRISTIANITY TODAY

    • Faith vs. Statistics, by Charles Colson (February 2003, Vol. 47, No. 2, Page 144, 10 printed pages)

You have permission to make up to 1,000 copies for use in your local church.

100% GUARANTEE - If you are not completely satisfied with the product you purchase, please e-mail us and we'll provide your next one completely free!



Word File BS090$5.95

Connect With Us :   E-Newsletter   |   Facebook   |   Twitter   |   RSS Feed